Articles Published in 2013

AB-Biotics, Scienta Farma partner to sell pharmacogenetic test in Mexico

Wednesday, October 2, 2013 01:18 PM

Spanish biotech company AB-Biotics and Scienta Farma reached an agreement to sell the pharmacogenetic test Neurofarmagen in Mexico. This test, developed by AB-Biotics, identifies the most optimum medication for each individual patient with depression, schizophrenia, bipolar disorder or epilepsy by analyzing DNA, extracted from a saliva sample.

More... »

Report: Prescription drug utilization among elderly Americans has reached plateau

Wednesday, October 2, 2013 01:16 PM

A new white paper from life sciences advisory firm VOI Consulting shows that while a confluence of technical, medical and social factors led to dramatic growth in per capita prescription drug consumption in the U.S. over the past 20 years, long-range forecast suggests consumption levels have reached a saturation point. This means the U.S. pharmaceutical market will not experience a similar wave of sustained, industry-wide growth in the foreseeable future.

More... »

Quest Diagnostics completes sale of Enterix to Clinical Genomics

Wednesday, October 2, 2013 01:15 PM

Quest Diagnostics, a provider of diagnostic information services, has completed the sale of its Enterix colorectal cancer screening test business to Clinical Genomics Technologies, an Australian life sciences company.

More... »

Soligenix awarded NIAID contract

Wednesday, October 2, 2013 01:14 PM

Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures (MCMs) for which there remains an unmet medical need, has been awarded a contract valued at up to $6.4 million by the U.S. Department of Health and Human Service's NIH (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID).

More... »

HμREL, Sanofi collaborate

Wednesday, October 2, 2013 01:12 PM

HμREL, a provider of advanced tissue constructs and microfluidic cell-based assay platforms for preclinical drug development, has entered into a multi-phase R&D collaboration with Sanofi U.S.

More... »

Viroclinics Biosciences launches clinical trial operations group

Wednesday, October 2, 2013 01:10 PM

Global CRO Viroclinics Biosciences has started a specialized group for clinical trial operations. Activities involve preparation of virology sampling kits, on-site sampling handling instruction, courier transport, sample tracking and tracing and management of sample processing labs.

More... »

National MS Society, GE Healthcare partner

Wednesday, October 2, 2013 01:08 PM

The National Multiple Sclerosis Society is collaborating with GE Healthcare through Fast Forward, a nonprofit subsidiary of the National Multiple Sclerosis Society, to co-fund a clinical study with the GE investigational PET tracer, GE180, in patients with multiple sclerosis (MS). The clinical study, which will be enrolling patients in the U.K., is aimed to aid in physicians' understanding of whether imaging neuroinflammation in MS patients before and after treatment with natalizumab (Tysabri) can help identify which patients may respond to treatment.

More... »

Amgen completes Onyx merger

Wednesday, October 2, 2013 01:01 PM

Amgen has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Onyx Pharmaceuticals for $125 per share in cash. As announced Aug. 25, the purchase price is $9.7 billion net of estimated Onyx cash.

More... »

Xention, Servier collaborate for atrial fibrillation treatment

Wednesday, October 2, 2013 12:59 PM

Xention, a Cambridge-based biopharmaceutical company specializing in discovery and development of ion channel-modulating drugs for atrial fibrillation (AF), and Servier, an independent French pharmaceutical company, have entered  a multi-year agreement for  development and commercialization of XEN-D0103, a selective Kv1.5 modulator discovered and developed by Xention for the treatment of AF.

More... »

ACRES, PharmaTrain form alliance

Wednesday, October 2, 2013 12:56 PM

The Alliance for Clinical Research Excellence and Safety (ACRES), a Cambridge, Mass.-based global nonprofit, and PharmaTrain Federation, an international nonprofit organization for improving education and training of professionals in medicines development, have allied to promote the adoption of new and reliable global standards for high-quality postgraduate education and training for individuals pursuing careers in discovery, development, regulation and marketing of new medicines.

More... »